Querbes
Olivier Querbes, Ramonville Saint-Agne FR
Patent application number | Description | Published |
---|---|---|
20140146142 | THREE-DIMENSIONAL MEASURING DEVICE USED IN THE DENTAL FIELD - The three dimensional measuring device used in the dental field and aimed at measuring in the absence of projection of active or structured light, includes an image-capturing device and data-processor for images. The image-capturing device is capable of simultaneously, or almost simultaneously, capturing at least two images, one of which is totally or partially included in the other one. The included image describes a narrower field than that of the other one, and has a higher accuracy than that of the other one. | 05-29-2014 |
Olivier Querbes, Esqualquens FR
Patent application number | Description | Published |
---|---|---|
20150350517 | DEVICE FOR VISUALIZING AN INTERIOR OF A PATIENT'S MOUTH - The device for visualizing the interior of a patient's mouth, includes a camera for taking an optical imprint of organs arranged in the mouth. The device includes augmented reality glasses having an optical glass through which a user of the glasses can see the inside of the mouth, and a visualization camera taking an image of what the user sees through the optical glass. First images corresponding to those taken by the visualization camera are correlated with second images corresponding to those taken by the camera for taking an optical imprint, whereby the second images can be projected onto the optical glass. | 12-03-2015 |
William Querbes, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110118340 | DELIVERY OF RNAI CONSTRUCTS TO OLIGODENDROCYTES - The invention provides methods for delivering a double-stranded nbonucleic acid (dsRNA) to the central nervous system of a subject, and particularly, to oligodendrocytes of a subject by localized delivery to the brain, e.g., to the corpus caïlosum. For example, the dsRNA molecules can include a first sequence that is selected from the Sroup consisting of the sense sequences of Tables 8, 10, 13-16, and a second sequence selected from the group consisting of the antisense sequences of Tables 8, 10, and 13-16. The dsRNA molecules can include naturally occurring nucleotides or can include at least one modified nucleotide, such as a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, or a terminal nucleotide linked to a conjugate group, such as to a cholesteryl derivative or a vitamin E group. Alternatively, the modified nucleotide may be chosen from the group consisting of a 2f-deoxy-2′-fliιioro modified nucleotide, a 2′-de-oxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural bas comprising nucleotide. Generally, such modified sequences will be based on a first sequence of a dsRNA selected from the group consisting of the sense sequences of Tables 8, 10, and 13-16, and a second sequence selected from the group consisting of the antisense sequences of Tables 8 10, and 13-16. | 05-19-2011 |
20120101148 | LIPID FORMULATION - The invention features an improved lipid formulation comprising a cationic lipid of formula (A), a neutral lipid, a sterol and a PEG or PEG-modified lipid, where R | 04-26-2012 |
20130281511 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1. | 10-24-2013 |
20140024699 | COMPOSITIONS AND METHODS FOR INCREASING ERYTHROPOIETIN (EPO) PRODUCTION - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes. | 01-23-2014 |
20150111841 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1. | 04-23-2015 |
William Querbes, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20140179768 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions. | 06-26-2014 |